All
National Science Foundation Awards Multimillion Grant in Pharmaceutical Manufacturing
May 25th 2006Rutgers, the state university of New Jersey (New Brunswick, NJ), the New Jersey Institute of Technology (Newark, NJ), Purdue University (West Lafayette, IN), and the University of Puerto Rico (Mayag?ez, PR) won a $15-million, five-year grant from the National Science Foundation (Arlington, VA) to improve the manufacturing of pharmaceuticals, food, and agricultural products.
CDER and CBER Issue Guidance on ICH Q8 Manufacturing Submissions
May 25th 2006The CDER and CBER have released a new "Guidance for Industry: Q8 Pharmaceutical Development," outlining what drug manufacturers should include in the Pharmaceutical Development section of International Council on Harmonization (ICH) Common Technical Document (CTD) submissions.
Report Focuses on Pharmaceutical Logistics in China
May 25th 2006Research and Markets (Dublin, Ireland) has released ?Annual Investment Analysis Report of the Chinese Pharmaceutical Logistics Industry, 2005-2006.? The report provides analysis of the pharmaceutical logistics characteristics, conditions, pharmaceutical market and pharmaceutical retail dynamics.
Standards Committee for Industrial Wireless Networks
May 11th 2006Seven automation suppliers have joined with users on the Instrumentation, Systems, and Automation Society (ISA, Research Triangle Park, NC) "Wireless Standards for Automation (SP100)" committee to develop wireless network structures for manufacturing plants.
Merck To Acquire Biologics Companies GlycoFi and Abmaxis
May 11th 2006Merck & Co Inc. (Whitehouse Station, NJ) has agreed to acquire two biologics companies: GlycoFi Inc. (Lebanon, NH), a specialist in yeast glycoengineering for $400 million, and the biopharmaceutical company Abmaxis Inc. (Santa Clara, CA) for $80 million.
FDA Withdraws Jan. 17 Rule Relaxing Phase I GMP Standards
May 4th 2006In a May 2 Federal Register notice (1), the US Food and Drug Administration withdrew its Jan. 17 direct final rule, "Current Good Manufacturing Practice Regulation and Investigational New Drugs" (2), which would have exempted manufacturing of drugs for Phase I clinical trials from most provisions of 21 CFR 211.
Clariant Divests Pharmaceutical Fine Chemicals Business
May 4th 2006Clariant (Muttenz, Switzerland) has agreed to sell its pharmaceutical fine chemicals unit to the private equity firm TowerBrook Capital Partners LP (New York, NY) for CHF 110 million ($89 million). The price includes an earn-out participation of CHF 40 million ($32 million) to be paid in two years.